Literature DB >> 11134311

Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat.

K Verhoef1, G Marzio, W Hillen, H Bujard, B Berkhout.   

Abstract

Live-attenuated human immunodeficiency virus type 1 (HIV-1) variants have shown great promise as AIDS vaccines, but continued replication can lead to the selection of faster-replicating variants that are pathogenic. We therefore designed HIV-1 genomes that replicate exclusively upon addition of the nontoxic effector doxycycline (dox). This was achieved by replacement of the viral TAR-Tat system for transcriptional activation by the Escherichia coli-derived Tet system for inducible gene expression. These designer "HIV-rtTA" viruses replicate in a strictly dox-dependent manner both in a T-cell line and in primary blood cells, and the rate of replication can be fine-tuned by simple variation of the dox concentration. These HIV-rtTA viruses provide a tool to perform genetics, e.g., selection and optimization experiments, with the E. coli-derived Tet reagents in a eukaryotic background. Furthermore, such viruses may represent improved vaccine candidates because their replication can be turned on and off at will.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11134311      PMCID: PMC113994          DOI: 10.1128/JVI.75.2.979-987.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

2.  A general and fast method to generate multiple site directed mutations.

Authors:  I Mikaelian; A Sergeant
Journal:  Nucleic Acids Res       Date:  1992-01-25       Impact factor: 16.971

3.  Premature strand transfer by the HIV-1 reverse transcriptase during strong-stop DNA synthesis.

Authors:  B Klaver; B Berkhout
Journal:  Nucleic Acids Res       Date:  1994-01-25       Impact factor: 16.971

4.  Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI.

Authors:  K Peden; M Emerman; L Montagnier
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

5.  Comparison of 5' and 3' long terminal repeat promoter function in human immunodeficiency virus.

Authors:  B Klaver; B Berkhout
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

6.  In vivo selection of randomly mutated retroviral genomes.

Authors:  B Berkhout; B Klaver
Journal:  Nucleic Acids Res       Date:  1993-11-11       Impact factor: 16.971

7.  Upstream U3 sequences in simian immunodeficiency virus are selectively deleted in vivo in the absence of an intact nef gene.

Authors:  F Kirchhoff; H W Kestler; R C Desrosiers
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

9.  Human immunodeficiency viruses regulated by alternative trans-activators: genetic evidence for a novel non-transcriptional function of Tat in virion infectivity.

Authors:  L M Huang; A Joshi; R Willey; J Orenstein; K T Jeang
Journal:  EMBO J       Date:  1994-06-15       Impact factor: 11.598

10.  Evolution of a disrupted TAR RNA hairpin structure in the HIV-1 virus.

Authors:  B Klaver; B Berkhout
Journal:  EMBO J       Date:  1994-06-01       Impact factor: 11.598

View more
  42 in total

1.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.

Authors:  G Marzio; K Verhoef; M Vink; B Berkhout
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors.

Authors:  Kylene Kehn-Hall; Irene Guendel; Lawrence Carpio; Leandros Skaltsounis; Laurent Meijer; Lena Al-Harthi; Joseph P Steiner; Avindra Nath; Olaf Kutsch; Fatah Kashanchi
Journal:  Virology       Date:  2011-04-22       Impact factor: 3.616

Review 3.  HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms.

Authors:  Atze T Das; Ben Berkhout
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-06-27       Impact factor: 6.237

4.  P-TEFb kinase complex phosphorylates histone H1 to regulate expression of cellular and HIV-1 genes.

Authors:  Siobhan K O'Brien; Hong Cao; Robin Nathans; Akbar Ali; Tariq M Rana
Journal:  J Biol Chem       Date:  2010-06-15       Impact factor: 5.157

5.  A doxycycline-dependent human immunodeficiency virus type 1 replicates in vivo without inducing CD4+ T-cell depletion.

Authors:  Nicolas Legrand; Gisela J van der Velden; Raphaël Ho Tsong Fang; Marc Douaisi; Kees Weijer; Atze T Das; Bianca Blom; Christel H Uittenbogaart; Ben Berkhout; Mireille Centlivre
Journal:  J Gen Virol       Date:  2012-05-30       Impact factor: 3.891

6.  Construction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication.

Authors:  Atze T Das; Bep Klaver; Alex Harwig; Monique Vink; Marcel Ooms; Mireille Centlivre; Ben Berkhout
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

7.  Macrophages archive HIV-1 virions for dissemination in trans.

Authors:  Natalia Sharova; Catherine Swingler; Mark Sharkey; Mario Stevenson
Journal:  EMBO J       Date:  2005-05-26       Impact factor: 11.598

Review 8.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

9.  The HIV-1 Tat protein has a versatile role in activating viral transcription.

Authors:  Atze T Das; Alex Harwig; Ben Berkhout
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

10.  Towards a genetic AIDS vaccine.

Authors:  Antonia V Bordería; Ben Berkhout
Journal:  Retrovirology       Date:  2009-10-16       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.